Mutual Advisors LLC Makes New $6.04 Million Investment in Hinge Health Inc. $HNGE

Key Points

• Mutual Advisors LLC acquired 130,003 shares of Hinge Health in Q4, a new stake valued at approximately $6.04 million representing about 0.17% of the company.
• Company insiders have been active sellers: CEO Daniel Antonio Perez sold 166,665 shares (~$6.71M) and insiders collectively sold 442,670 shares valued at roughly $18.79 million in the past 90 days.
• Hinge Health recently beat quarterly expectations with $0.49 EPS vs. $0.04 consensus and revenue of $170.73M (up 45.5% YoY); analysts' consensus is a "Moderate Buy" with an average target of $56.73.

Mutual Advisors LLC acquired a new stake in Hinge Health Inc. (NYSE:HNGE - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 130,003 shares of the company's stock, valued at approximately $6,039,000. Mutual Advisors LLC owned 0.17% of Hinge Health as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of HNGE. Vanguard Group Inc. raised its holdings in Hinge Health by 22.6% in the 3rd quarter. Vanguard Group Inc. now owns 1,237,839 shares of the company's stock valued at $60,753,000 after buying an additional 228,234 shares during the last quarter. Tudor Investment Corp ET AL raised its holdings in Hinge Health by 25.9% in the 3rd quarter. Tudor Investment Corp ET AL now owns 376,266 shares of the company's stock valued at $18,467,000 after buying an additional 77,464 shares during the last quarter. First Eagle Investment Management LLC bought a new position in Hinge Health in the 3rd quarter valued at approximately $4,074,000. Braidwell LP bought a new position in Hinge Health in the 3rd quarter valued at approximately $44,686,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Hinge Health by 755.1% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 27,354 shares of the company's stock valued at $1,271,000 after buying an additional 24,155 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on HNGE. Freedom Capital upgraded shares of Hinge Health to a "strong-buy" rating in a report on Thursday, January 22nd. Wells Fargo & Company began coverage on shares of Hinge Health in a research report on Thursday, January 8th. They set an "overweight" rating and a $68.00 target price for the company. Barclays decreased their target price on shares of Hinge Health from $60.00 to $52.00 and set an "overweight" rating for the company in a research report on Wednesday, February 11th. Wall Street Zen downgraded shares of Hinge Health from a "buy" rating to a "hold" rating in a research report on Saturday. Finally, Evercore reissued an "outperform" rating and set a $45.00 target price on shares of Hinge Health in a research report on Wednesday, April 8th. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Hinge Health currently has an average rating of "Moderate Buy" and an average target price of $56.73.

Insider Buying and Selling

In other Hinge Health news, CEO Daniel Antonio Perez sold 166,665 shares of the firm's stock in a transaction on Thursday, February 12th. The stock was sold at an average price of $40.26, for a total transaction of $6,709,932.90. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO James Budge sold 11,006 shares of the firm's stock in a transaction on Monday, March 23rd. The shares were sold at an average price of $42.26, for a total value of $465,113.56. Following the transaction, the chief financial officer owned 401,427 shares in the company, valued at approximately $16,964,305.02. This trade represents a 2.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 442,670 shares of company stock valued at $18,786,901 in the last 90 days.

Hinge Health Trading Up 1.8%

Shares of NYSE:HNGE opened at $45.42 on Friday. The stock's fifty day simple moving average is $42.03 and its two-hundred day simple moving average is $44.03. Hinge Health Inc. has a 1-year low of $30.08 and a 1-year high of $62.18. The stock has a market cap of $3.58 billion and a PE ratio of -3.55.

Hinge Health (NYSE:HNGE - Get Free Report) last issued its quarterly earnings data on Tuesday, February 10th. The company reported $0.49 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.45. The company had revenue of $170.73 million for the quarter, compared to the consensus estimate of $157.31 million. The business's revenue was up 45.5% on a year-over-year basis. On average, sell-side analysts forecast that Hinge Health Inc. will post 0.78 earnings per share for the current fiscal year.

About Hinge Health

Hinge Health NYSE: HNGE is a digital musculoskeletal (MSK) clinic that provides end-to-end solutions for the prevention and management of musculoskeletal conditions. The company's platform combines wearable motion sensors, personalized exercise therapy guided by licensed physical therapists, and behavioral health coaching to deliver tailored treatment plans. By integrating technology with evidence-based clinical protocols, Hinge Health aims to reduce pain, improve mobility and decrease reliance on more invasive interventions such as surgery or opioid prescriptions.

Founded in 2015 and headquartered in San Francisco, Hinge Health partners with employers, health plans and other payers to offer its self-directed, app-based programs.

Want to see what other hedge funds are holding HNGE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hinge Health Inc. (NYSE:HNGE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.